Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Low Recruitment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main purpose of this study is the identification, description, and segmentation of non-small cell lung cancer (NSCLC) patients based on their value appraisal of treatment outcomes and all intermediate states of health, to obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC (stage IIIB / IV) who are in transition from 1st to 2nd line treatment, and to gain utility scores by health state derived from patients' perceived value and taken from their perspective.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Regular treatment for non-small cell lung cancer (NSCLC) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| To obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC stage IIb/IV who are in transition from 1st line to 2nd line treatment | once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy |
| Measure | Description | Time Frame |
|---|---|---|
| current medical practice treatment objectives and modalities side effects | once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy | |
| socioeconomic status and demographics patients' perception of their health status and treatment patient values and patient preferences |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients suffering from non-small cell lung cancer (NSCLC) (stage IIIb and IV) undergoing chemotherapy, who are in transition from 1st to 2nd line treatment.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Christopher Teale | AstraZeneca UK Limited, Alderley House, Alderley Park, Macclesfield SK10 4TF, Cheshire, United Kingdom, Phone: +44 1625 516549 Fax: +44 1625 518982 | Study Director |
| Oliver Fietz, PhD | AstraZeneca GmbH, Tinsdaler Weg 18322880, Wedel, Germany, Phone: +49 (0) 4103 708-3096 Fax: +49 (0) 4103 708-7-3096 | Study Chair |
| Helge Bischoff, MD | Thoraxklinik Heidelberg, gGmbH, Amalienstr. 5, 69126 Heidelberg, Germany, Phone: +49 (0) 6221 396-1304 Fax: +49 (0) 6221 396-1305 | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Berlin | Germany | ||||
| Research Site |
Not provided
Not provided
Not provided
Not provided
| once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy |
| Essen |
| Germany |
| Research Site | Heidelberg | Germany |
| Research Site | Hemer | Germany |
| Research Site | Karlsruhe | Germany |
| Research Site | Löwenstein | Germany |
| Research Site | München | Germany |
| Research Site | Trier | Germany |
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| D002289 | Carcinoma, Non-Small-Cell Lung |
| D057240 | Patient Preference |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D017060 | Patient Satisfaction |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
| D001519 | Behavior |
Not provided
Not provided